Skip to main content
. Author manuscript; available in PMC: 2013 Sep 6.
Published in final edited form as: Cancer Res. 2012 Mar 9;72(9):2239–2250. doi: 10.1158/0008-5472.CAN-11-3016

Figure 7. Tumor growth and angiogenesis are reduced in ant-VEGF or combined anti-VEGF anti-Bv8 treated Ceacam1−/− mice.

Figure 7

(A) Anti-VEGF, anti-Bv8, or combined blocking antibodies reduced tumor growth (n=6 mice per group) in Ceacam1−/− mice bearing B16 tumors. Data represent mean ± SEM, *P ≤0.01. (B) Blood vessels in tumors were counted based on immunohistological analysis with anti-CD31 of frozen tumor tissue collected from mice in (A) after 17 days. More than 8 fields of view were analyzed. Data represent mean ± SEM. **0.001< P ≤ 0.01. (C) Immunofluorescent staining of tumor associated Gr1+ cells. Data represent mean ± SEM. **0.001< P ≤ 0.01.